132 related articles for article (PubMed ID: 24965401)
1. Primary neuroendocrine carcinoma of the breast.
Lu CS; Huang SH; Ho CL; Chen JH; Chao TY
J BUON; 2014; 19(2):419-29. PubMed ID: 24965401
[TBL] [Abstract][Full Text] [Related]
2. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
4. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast.
Cloyd JM; Yang RL; Allison KH; Norton JA; Hernandez-Boussard T; Wapnir IL
Breast Cancer Res Treat; 2014 Dec; 148(3):637-44. PubMed ID: 25399232
[TBL] [Abstract][Full Text] [Related]
5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.
McCann GA; Boutsicaris CE; Preston MM; Backes FJ; Eisenhauer EL; Fowler JM; Cohn DE; Copeland LJ; Salani R; O'Malley DM
Gynecol Oncol; 2013 Apr; 129(1):135-9. PubMed ID: 23357610
[TBL] [Abstract][Full Text] [Related]
7. [Primary neuroendocrine tumors of the breast: a retrospective study of 21 cases and literature review].
Feki J; Fourati N; Mnif H; Khabir A; Toumi N; Khanfir A; Boudawara T; Amouri H; Daoud J; Frikha M
Cancer Radiother; 2015 Aug; 19(5):308-12. PubMed ID: 26215367
[TBL] [Abstract][Full Text] [Related]
8. Male breast cancer: a survey at the Helsinki University Central Hospital during 1981-2006.
Liukkonen S; Saarto T; Mäenpää H; Sjöström-Mattson J
Acta Oncol; 2010 Apr; 49(3):322-7. PubMed ID: 20397767
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Male breast cancer: a retrospective study of 15 years.
Eryilmaz MA; Igci A; Muslumanoglu M; Ozmen V; Koc M
J BUON; 2012; 17(1):51-6. PubMed ID: 22517693
[TBL] [Abstract][Full Text] [Related]
13. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
Ma XM; Han YW; Zhang J; Cui WJ; Wang X
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
[TBL] [Abstract][Full Text] [Related]
14. A rare breast tumor: solid neuroendocrine carcinoma.
Sanguinetti A; Santoprete S; Lucchini R; Triola R; Loreti F; Avenia N
Ann Ital Chir; 2013; 84(1):81-5. PubMed ID: 22672972
[TBL] [Abstract][Full Text] [Related]
15. Male breast cancer in the veterans affairs population: a comparative analysis.
Nahleh ZA; Srikantiah R; Safa M; Jazieh AR; Muhleman A; Komrokji R
Cancer; 2007 Apr; 109(8):1471-7. PubMed ID: 17342768
[TBL] [Abstract][Full Text] [Related]
16. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
18. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
19. Male breast cancer: a retrospective analysis.
Yoney A; Kucuk A; Unsal M
Cancer Radiother; 2009 Apr; 13(2):103-7. PubMed ID: 19250851
[TBL] [Abstract][Full Text] [Related]
20. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
